Rome, Nov 9. (Adnkronos Health) – Europe slows down, China accelerates: between 2013 and 2023, the European share of new clinical trials launched worldwide dropped from 18% to 9%, while China’s rose from 8% to 29% (Efpia 2025 Data). To avoid falling behind, Lombardy is focusing on partnerships, digital transformation, and competitiveness. This was discussed yesterday in Bergamo during the event organized by Bion – Lombardy Life Sciences Cluster, as part of the new Academy on Clinical Research launched in 2026. The ‘Clinical Research Forum’ was organized in collaboration with Ieo (European Institute of Oncology), From Foundation, and Asst Grande Ospedale Metropolitano Niguarda, with the support of Asst Papa Giovanni XXIII and Lombardy Region, under the patronage and collaboration of Afi (Pharmaceutical Industry Association), Frrb (Regional Foundation for Biomedical Research), Fiaso, Gidm (Italian Data Manager Group), and Simef (Italian Society of Pharmaceutical Medicine). During the day – a note informs – discussions covered regional policies, the role of territorial Ethics Committees, aggregation models such as Clinical Trial Centers and the actions of institutions and research centers, the centrality of the patient and their involvement already in the study design, artificial intelligence, and data governance. Many topics, many shared perspectives, but a single objective: to identify priorities for the competitiveness of the Lombardy System, from Research funds to the Welfare policies of the Lombardy Region.
“The numbers tell us that clinical research is shifting towards other areas of the world, but also the capacity for attraction differs among European countries, and unfortunately, our country seems to be slowing down – explains Gianluca Vago, president of Bion –. With the Cluster, we have tried to discuss and delve into the reasons contributing to these delays, and to suggest possible interventions that can help us be attractive and preserve the value of non-profit research, which has shown a slowdown at the national level. As became clear thanks to the contributions of the various components involved in the authorization and operational processes, we believe that Lombardy can try to correct some of the dynamics that hinder and slow down participation in the most important clinical studies, focusing on monitoring, planning, and digital innovation. Consistent regional policies are needed, bureaucratic simplification to make the analysis and approval phases by ethics committees faster and more reliable, a more favorable interpretation of the necessary personal data protection regulations, homogeneous standards within which to operate, in line with European Union guidelines. And furthermore, the involvement not only formal but structural and competent of patients, already in the study design definition phases. In a research we promoted this year, moreover, the need emerged to strengthen structures with human resources that are as stable as possible, as well as the need to increase digitalization rates for effective data utilization; data warehouses are still not very widespread (in about 37% of the interviewed sample). With this Forum, we wanted to offer an opportunity for in-depth analysis and discussion to aim at making Lombardy a possible laboratory for scalable solutions for the entire country.”
The study, conducted by Bion in collaboration with Iqvia with the participation of 19 regional centers, highlighted some priority guidelines for research. These include shared standards, a regional data warehouse to support research, and the review and recognition of research personnel roles, with priority given to training and secondary use of data.